Public Release: 

New leadless pacemaker safe, reliable

Abstract 16158 (Room S401bcd, Core 4)

American Heart Association

A new self-contained leadless cardiac pacemaker is a safe and reliable alternative to conventional pacemakers, according to research presented at the American Heart Association's Scientific Sessions 2014.

The new device reduces complications that have existed over the last 50 years that are associated with lead placement and performance and the pulse generator situated under the skin that have occurred with conventional pacemaker systems.

In the first trial of the leadless pacemaker, doctors implanted one in eight patients (average 82 years old, 75 percent men) with no complications in an average 41 minutes.

Researchers measured the device's performance at implant, after the patient was discharged and during three-, six- and twelve-month follow-up sessions.

The study, which began in December 2012, will continue until researchers have performance and safety results at 18 months.

###

Fleur Tjong, M.D., research fellow in cardiology, Academic Medical Center, Amsterdam, The Netherlands

Additional Resources:

  • Available multimedia resources (photos/videos/graphics) are available on the right column of the release link http://newsroom.heart.org/news/wednesday-news-tips-2775517?preview=780d31711ac1ba6d7bc980c673cf3069

  • For more news from AHA's Scientific Sessions, follow us on Twitter @HeartNews #AHA14

    Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at http://www.heart.org/corporatefunding.

    For Media Inquiries:

    AHA News Media in Dallas: (214) 706-1173

    AHA News Media Office, Nov. 15-19,

    at the McCormick Place Convention Center: (312) 949-3400

    For Public Inquiries: (800) AHA-USA1 (242-8721)

    heart.org and strokeassociation.org

    Life is why we fund scientific breakthroughs that save and improve lives.

  • Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.